JPMorgan Chase & Co. Has $8.14 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

JPMorgan Chase & Co. trimmed its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 13.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,086,327 shares of the company's stock after selling 168,971 shares during the period. JPMorgan Chase & Co. owned about 0.79% of Vir Biotechnology worth $8,137,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of VIR. Charles Schwab Investment Management Inc. lifted its holdings in shares of Vir Biotechnology by 13.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company's stock valued at $8,496,000 after purchasing an additional 136,087 shares in the last quarter. State Street Corp lifted its stake in Vir Biotechnology by 10.4% in the third quarter. State Street Corp now owns 5,625,533 shares of the company's stock valued at $42,135,000 after buying an additional 530,645 shares in the last quarter. Affinity Asset Advisors LLC acquired a new position in shares of Vir Biotechnology in the second quarter valued at approximately $1,780,000. Point72 Hong Kong Ltd increased its position in shares of Vir Biotechnology by 180.6% during the second quarter. Point72 Hong Kong Ltd now owns 19,572 shares of the company's stock worth $174,000 after acquiring an additional 12,598 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Vir Biotechnology by 94.6% during the second quarter. Millennium Management LLC now owns 1,248,131 shares of the company's stock worth $11,108,000 after acquiring an additional 606,804 shares during the period. 65.32% of the stock is currently owned by institutional investors.

Insider Transactions at Vir Biotechnology

In other news, Director Vicki L. Sato sold 10,960 shares of the firm's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total transaction of $137,219.20. Following the completion of the sale, the director now owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. This trade represents a 0.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 14,786 shares of company stock worth $170,172 in the last ninety days. Insiders own 15.60% of the company's stock.

Wall Street Analysts Forecast Growth

VIR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their target price on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a research note on Thursday, January 9th. HC Wainwright reiterated a "buy" rating and set a $110.00 price objective on shares of Vir Biotechnology in a report on Friday, January 10th. Morgan Stanley upgraded Vir Biotechnology from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. Leerink Partners upped their price target on Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday. Finally, Barclays lowered their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $34.83.

Vir Biotechnology Price Performance

VIR stock traded up $0.27 during mid-day trading on Wednesday, reaching $10.50. The company had a trading volume of 2,214,851 shares, compared to its average volume of 6,511,536. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -2.68 and a beta of 0.51. Vir Biotechnology, Inc. has a 52 week low of $6.56 and a 52 week high of $14.45. The stock has a 50 day simple moving average of $8.27 and a two-hundred day simple moving average of $8.37.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm had revenue of $2.38 million during the quarter, compared to the consensus estimate of $5.54 million. During the same period in the prior year, the business posted ($1.22) earnings per share. Vir Biotechnology's quarterly revenue was down 9.8% compared to the same quarter last year. On average, equities analysts predict that Vir Biotechnology, Inc. will post -3.36 EPS for the current year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).